Millendo Therapeutics (NASDAQ:MLND) Raised to Buy at ValuEngine

ValuEngine upgraded shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a buy rating in a report issued on Thursday morning, ValuEngine reports.

MLND has been the topic of a number of other reports. Wedbush started coverage on Millendo Therapeutics in a research report on Thursday, July 18th. They issued an outperform rating and a $24.00 price target on the stock. Citigroup started coverage on Millendo Therapeutics in a research note on Monday, July 15th. They issued an outperform rating and a $26.00 price objective on the stock. CIBC started coverage on Millendo Therapeutics in a research note on Tuesday, July 16th. They issued an outperform rating and a $26.00 price objective on the stock. Oppenheimer started coverage on Millendo Therapeutics in a research note on Tuesday, July 16th. They issued an outperform rating and a $26.00 price objective on the stock. Finally, Zacks Investment Research raised Millendo Therapeutics from a sell rating to a hold rating in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Millendo Therapeutics presently has a consensus rating of Buy and an average price target of $24.38.

NASDAQ:MLND traded down $0.18 during trading hours on Thursday, reaching $8.56. The company had a trading volume of 8,557 shares, compared to its average volume of 36,910. The business has a 50-day simple moving average of $11.44. Millendo Therapeutics has a one year low of $6.77 and a one year high of $17.34. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83.

Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.08). Research analysts expect that Millendo Therapeutics will post -3.32 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of MLND. BlackRock Inc. acquired a new position in Millendo Therapeutics during the fourth quarter worth about $203,000. Geode Capital Management LLC purchased a new position in Millendo Therapeutics in the 4th quarter worth about $113,000. Tibra Equities Europe Ltd purchased a new position in Millendo Therapeutics in the 1st quarter worth about $303,000. Private Advisors LLC increased its stake in Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after purchasing an additional 1,279 shares in the last quarter. Finally, Strs Ohio purchased a new position in Millendo Therapeutics in the 2nd quarter worth about $28,000. 44.06% of the stock is currently owned by institutional investors.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Recommended Story: What is the formula for calculating total return?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.